Atara Biotherapeutics, Inc. (ATRA): Price and Financial Metrics

Atara Biotherapeutics, Inc. (ATRA): $0.39

0.03 (-7.04%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add ATRA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#95 of 352

in industry

ATRA Price/Volume Stats

Current price $0.39 52-week high $2.54
Prev. close $0.42 52-week low $0.20
Day low $0.37 Volume 2,595,800
Day high $0.42 Avg. volume 2,256,051
50-day MA $0.62 Dividend yield N/A
200-day MA $0.85 Market Cap 47.52M

ATRA Stock Price Chart Interactive Chart >


Atara Biotherapeutics, Inc. (ATRA) Company Bio


Atara Biotherapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. The company was founded in 2012 and is based in South San Francisco, California.


ATRA Latest News Stream


Event/Time News Detail
Loading, please wait...

ATRA Latest Social Stream


Loading social stream, please wait...

View Full ATRA Social Stream

Latest ATRA News From Around the Web

Below are the latest news stories about ATARA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ATRA as an investment opportunity.

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

THOUSAND OAKS, Calif., December 20, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). Building on the earlier partnership announced in October 2021 to commercialize tab-c

Yahoo | December 20, 2023

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

THOUSAND OAKS, Calif., December 11, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. Findings support ATA3431 advancement into clinical testing, i

Yahoo | December 11, 2023

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif., December 01, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under th

Yahoo | December 1, 2023

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

THOUSAND OAKS, Calif., November 29, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving

Yahoo | November 29, 2023

Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why

Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.

Yahoo | November 24, 2023

Read More 'ATRA' Stories Here

ATRA Price Returns

1-mo -45.07%
3-mo -41.70%
6-mo -28.06%
1-year -79.58%
3-year -97.40%
5-year -98.18%
YTD -23.95%
2023 -84.37%
2022 -79.19%
2021 -19.71%
2020 19.19%
2019 -52.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!